Drug intelligence / Profile preview

montelukast + zafirlukast

Development stage: Discontinued
Modality: Small Molecules
Administration: Oral

Overview

This is a combination of two leukotriene receptor antagonists, montelukast and zafirlukast. Both drugs work by blocking the cysteinyl leukotriene receptor, reducing inflammation and bronchoconstriction in the airways. However, combined administration of these drugs is not recommended due to potential drug interactions. Each drug individually is used for the treatment of asthma and allergic conditions.

Targets

CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)ADORA3 (Adenosine A3 receptor)MAPK3 (Mitogen-activated protein kinase 1)MAPK14 (p38 mitogen-activated protein kinase alpha)

Beyond the preview

Go deeper on montelukast + zafirlukast.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on montelukast + zafirlukast.

Explore the full profile